485 Shares in Regeneron Pharmaceuticals, Inc. (REGN) Purchased by Moors & Cabot Inc.

Moors & Cabot Inc. acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to its most recent filing with the SEC. The fund acquired 485 shares of the biopharmaceutical company’s stock, valued at approximately $217,000.

Several other large investors also recently added to or reduced their stakes in the stock. Sequoia Financial Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 1.7% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 712 shares of the biopharmaceutical company’s stock valued at $350,000 after purchasing an additional 12 shares during the period. Capital Planning Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 2.1% during the 2nd quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 12 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Regeneron Pharmaceuticals by 0.4% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 5,661 shares of the biopharmaceutical company’s stock worth $2,780,000 after buying an additional 20 shares in the last quarter. National Asset Management Inc. grew its position in Regeneron Pharmaceuticals by 3.1% during the second quarter. National Asset Management Inc. now owns 856 shares of the biopharmaceutical company’s stock worth $421,000 after buying an additional 26 shares in the last quarter. Finally, Sterling Investment Advisors Ltd. grew its position in Regeneron Pharmaceuticals by 11.2% during the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 28 shares in the last quarter. Institutional investors own 66.67% of the company’s stock.

Several equities analysts recently commented on the company. Royal Bank of Canada restated a “hold” rating and set a $430.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday. Deutsche Bank assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 12th. They set a “hold” rating and a $397.00 target price for the company. TheStreet cut Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Thursday, November 30th. Citigroup cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $480.00 to $380.00 in a research report on Friday, December 1st. Finally, J P Morgan Chase & Co restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, November 28th. Two equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $465.40.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at $388.95 on Friday. The firm has a market capitalization of $42,420.00, a PE ratio of 33.17, a P/E/G ratio of 1.51 and a beta of 1.53. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $340.09 and a fifty-two week high of $543.55. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating the consensus estimate of $3.83 by $0.16. The company had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. Regeneron Pharmaceuticals’s quarterly revenue was up 23.0% compared to the same quarter last year. During the same period in the prior year, the business posted $3.13 EPS. equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total transaction of $712,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Charles A. Baker sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $450.00, for a total value of $900,000.00. Following the transaction, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The disclosure for this sale can be found here. Corporate insiders own 10.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “485 Shares in Regeneron Pharmaceuticals, Inc. (REGN) Purchased by Moors & Cabot Inc.” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.com-unik.info/2017/12/17/485-shares-in-regeneron-pharmaceuticals-inc-regn-purchased-by-moors-cabot-inc.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

What are top analysts saying about Regeneron Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regeneron Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit